Top of page
Global Site Navigation

School of Medical and Health Sciences

Local Section Navigation
You are here: Main Content

Miss Anna Reid

Research Assistant

Staff Member Details
Telephone: +61 8 6304 2803
Email: anna.reid@ecu.edu.au
Campus: Joondalup  

Anna is a Research Assistant within the School of Medical and Health Sciences.

Qualifications

  • Bachelor of Science in Biomedical Sciences, Murdoch University, 2008.

Research Outputs

Journal Articles

  • Khattak, M., Reid, A., Freeman, J., Pereira, M., McEvoy, A., Lo, J., Frank, M., Meniawy, T., Didan, A., Spencer, I., Amanuel, B., Millward, M., Ziman, M., Gray, E. (2020). PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. The Oncologist, 25(3), e520-e527. https://doi.org/10.1634/theoncologist.2019-0557.
  • Marsavela, G., Lee, J., Calapre, L., Wong, S., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Abed, A., Khattak, M., Meniawy, T., Dawson, S., Sandhu, S., Carlino, M., Menzies, A., Scolyer, R., Long, G., Amanuel, B., Millward, M., Ziman, M., Rizos, H., Gray, E. (2020). Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 26(22), 5926-5933. https://doi.org/10.1158/1078-0432.CCR-20-2251.
  • Warburton, L., Calapre, L., Pereira, M., Reid, A., Robinson, C., Amanuel, B., Ziman, M., Millward, M., Gray, E. (2020). Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. Cancers, 12(11), Article number 3486. https://doi.org/10.3390/cancers12113486.
  • Marsavela, G., Johansson, P., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Khattak, M., Meniawy, T., Amanuel, B., Millward, M., Hayward, N., Ziman, M., Gray, E., Calapre, L. (2020). The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond BRAF Mutant Detection. Cancers, 12(12), Article number 3793. https://doi.org/10.3390/cancers12123793.
  • Khattak, M., Abed, A., Reid, A., McEvoy, A., Millward, M., Ziman, M., Gray, E. (2020). Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study. Frontiers in Oncology, 10(30 June 2020), Article number 1041. https://doi.org/10.3389/fonc.2020.01041.

Journal Articles

  • Calapre, L., Giardina, T., Robinson, C., Reid, A., Al-Ogaili, Z., Pereira, M., McEvoy, A., Warburton, L., Hayward, N., Khattak, M., Meniawy, T., Millward, M., Amanuel, B., Ziman, M., Gray, E. (2019). Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Molecular Oncology, 13(2), 171-184. https://doi.org/10.1002/1878-0261.12391.
  • McEvoy, A., Pereira, M., Reid, A., Pearce, R., Cowell, L., Al-Ogaili, Z., Khattak, M., Millward, M., Meniawy, T., Gray, E., Ziman, M. (2019). Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget, 10(2), 113-122. https://doi.org/10.18632/oncotarget.26451.
  • Osborne, D., Domenico, J., Luo, Y., Reid, A., Amato, C., Zhai, Z., Gao, D., Ziman, M., Dinarello, C., Robinson, W., Fujita, M. (2019). Interleukin‐37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome. Molecular Carcinogenesis, 58(9), 1670-1679. https://doi.org/10.1002/mc.23044.
  • Aya-Bonilla, C., Gray, E., Manikandan, J., Freeman, J., Zaenker, P., Reid, A., Khattak, M., Frank, M., Millward, M., Ziman, M. (2019). Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles. Cancers, 11(2), Article number 157. https://doi.org/10.3390/cancers11020157.

Journal Articles

  • Dunkel, Y., Reid, A., Ear, J., Aznar, N., Millward, M., Gray, E., Pearce, R., Ziman, M., Ghosh, P. (2018). Prognostic relevance of CCDC88C (Daple) transcripts in the peripheral blood of patients with cutaneous melanoma. Scientific Reports, 8(1), Article number 18036. https://doi.org/10.1038/s41598-018-36173-x.

Journal Articles

  • Gray, E., Rizos, H., Reid, A., Boyd, S., Pereira, M., Lo, J., Tembe, V., Freeman, J., Lee, J., Scolyer, R., Siew, K., Lomma, C., Cooper, A., Khattak, M., Meniawy, T., Long, G., Carlino, M., Millward, M., Ziman, M. (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 6(39), 42008-42018. https://doi.org/10.18632/oncotarget.5788.
  • Gray, E., Reid, A., Bowyer, S., Calapre, L., Siew, K., Pearce, R., Cowell, L., Frank, M., Millward, M., Ziman, M. (2015). Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. Journal of Investigative Dermatology, 135(8), 2040-2048. https://doi.org/10.1038/jid.2015.127.
  • Reid, A., Freeman, J., Millward, M., Ziman, M., Gray, E. (2015). Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clinical Biochemistry, 48(15), 999-1002. https://doi.org/10.1016/j.clinbiochem.2014.12.007.

Journal Articles

  • Klinac, D., Gray, E., Freeman, J., Reid, A., Bowyer, S., Millward, M., Ziman, M. (2014). Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer, 14(1), Article number 423. https://doi.org/10.1186/1471-2407-14-423.

Journal Articles

  • Reid, A., Millward, M., Pearce, R., Lee, M., Frank, M., Ireland, A., Monshizadeh, L., Rai, T., Heenan, P., Medic, S., Kumarasinghe, P., Ziman, M. (2013). Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. British Journal of Dermatology, 168(1), 85-92. https://doi.org/10.1111/bjd.12057.

Research Projects

  • Predictive significance of circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) and serum vascular endothelial growth factor (VEGF) in advanced melanoma patients treated with pembrolizumab, Merck Sharp and Dohme (Australia) Pty Ltd, Grant, 2016 ‑ 2019, $73,300.
  • Neon Transfection System and Biomedical Research Grade -30oC Freezer for Alzheimer’s and Melanoma Research, National Health and Medical Research Council, Equipment Grant 2011, 2011 ‑ 2012, $10,927.
Skip to top of page